XBiotech Inc.

NasdaqGS:XBIT Stock Report

Market Cap: US$75.6m

XBiotech Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Sushma Shivaswamy

Chief executive officer

US$657.6k

Total compensation

CEO salary percentage68.43%
CEO tenure8.1yrs
CEO ownershipn/a
Management average tenure8.1yrs
Board average tenure7.5yrs

Recent management updates

Recent updates

We're Hopeful That XBiotech (NASDAQ:XBIT) Will Use Its Cash Wisely

Nov 04
We're Hopeful That XBiotech (NASDAQ:XBIT) Will Use Its Cash Wisely

XBiotech (NASDAQ:XBIT) Is In A Good Position To Deliver On Growth Plans

Jun 16
XBiotech (NASDAQ:XBIT) Is In A Good Position To Deliver On Growth Plans

XBiotech (NASDAQ:XBIT) Has Debt But No Earnings; Should You Worry?

Dec 30
XBiotech (NASDAQ:XBIT) Has Debt But No Earnings; Should You Worry?

Is XBiotech (NASDAQ:XBIT) Weighed On By Its Debt Load?

Aug 30
Is XBiotech (NASDAQ:XBIT) Weighed On By Its Debt Load?

XBiotech: Several Shots On Goal In Big Target Market Indications

May 24

Is XBiotech (NASDAQ:XBIT) Using Debt In A Risky Way?

May 13
Is XBiotech (NASDAQ:XBIT) Using Debt In A Risky Way?

We're Not Very Worried About XBiotech's (NASDAQ:XBIT) Cash Burn Rate

Feb 09
We're Not Very Worried About XBiotech's (NASDAQ:XBIT) Cash Burn Rate

We're Hopeful That XBiotech (NASDAQ:XBIT) Will Use Its Cash Wisely

Oct 25
We're Hopeful That XBiotech (NASDAQ:XBIT) Will Use Its Cash Wisely

We Think Some Shareholders May Hesitate To Increase XBiotech Inc.'s (NASDAQ:XBIT) CEO Compensation

Jun 16
We Think Some Shareholders May Hesitate To Increase XBiotech Inc.'s (NASDAQ:XBIT) CEO Compensation

XBiotech (NASDAQ:XBIT) Is In A Good Position To Deliver On Growth Plans

May 11
XBiotech (NASDAQ:XBIT) Is In A Good Position To Deliver On Growth Plans

Read This Before Buying XBiotech Inc. (NASDAQ:XBIT) Shares

Mar 18
Read This Before Buying XBiotech Inc. (NASDAQ:XBIT) Shares

Here's Why We Don't Think XBiotech's (NASDAQ:XBIT) Statutory Earnings Reflect Its Underlying Earnings Potential

Jan 08
Here's Why We Don't Think XBiotech's (NASDAQ:XBIT) Statutory Earnings Reflect Its Underlying Earnings Potential

CEO Compensation Analysis

How has Sushma Shivaswamy's remuneration changed compared to XBiotech's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$29m

Jun 30 2025n/an/a

-US$28m

Mar 31 2025n/an/a

-US$39m

Dec 31 2024US$658kUS$450k

-US$39m

Sep 30 2024n/an/a

-US$33m

Jun 30 2024n/an/a

-US$35m

Mar 31 2024n/an/a

-US$31m

Dec 31 2023US$720kUS$445k

-US$25m

Sep 30 2023n/an/a

-US$23m

Jun 30 2023n/an/a

-US$28m

Mar 31 2023n/an/a

-US$31m

Dec 31 2022US$381kUS$376k

-US$33m

Sep 30 2022n/an/a

-US$36m

Jun 30 2022n/an/a

-US$27m

Mar 31 2022n/an/a

-US$20m

Dec 31 2021US$1mUS$376k

-US$17m

Sep 30 2021n/an/a

-US$13m

Jun 30 2021n/an/a

-US$12m

Mar 31 2021n/an/a

-US$14m

Dec 31 2020US$456kUS$300k

-US$11m

Sep 30 2020n/an/a

US$677m

Jun 30 2020n/an/a

US$673m

Mar 31 2020n/an/a

US$674m

Dec 31 2019US$1mUS$300k

US$669m

Sep 30 2019n/an/a

-US$24m

Jun 30 2019n/an/a

-US$23m

Mar 31 2019n/an/a

-US$23m

Dec 31 2018US$312kUS$306k

-US$21m

Compensation vs Market: Sushma's total compensation ($USD657.57K) is about average for companies of similar size in the US market ($USD576.67K).

Compensation vs Earnings: Sushma's compensation has been consistent with company performance over the past year.

CEO

Sushma Shivaswamy (47 yo)

8.1yrs
Tenure
US$657,572
Compensation

Dr. Sushma Shivaswamy is Chief Scientific Officer of XBiotech USA, Inc. Dr. Shivaswamy has been Chief Scientific Officer at XBiotech Inc. since November 20, 2017 and serves as its Interim Chief Executive O...

Leadership Team

NamePositionTenureCompensationOwnership
John Simard
Founder & Chairman20.8yrsUS$6.25m12.54%
$ 9.5m
Sushma Shivaswamy
Interim CEO & Chief Scientific Officer8.1yrsUS$657.57kno data
Angela Hu
Director of Finance2.8yrsUS$285.42k0.084%
$ 63.2k
8.1yrs
Average Tenure
47yo
Average Age

Experienced Management: XBIT's management team is seasoned and experienced (8.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
John Simard
Founder & Chairman20.8yrsUS$6.25m12.54%
$ 9.5m
Tak Mak
Director1yrno datano data
Thomas Kündig
Independent Directorless than a yearno data0.98%
$ 744.0k
Peter Libby
Member of Scientific Advisory Board & Independent Director7.3yrsUS$193.30k0.082%
$ 62.0k
Alice Gottlieb
Member of Scientific Advisory Board7.3yrsno datano data
Alexander Knuth
Member of Scientific Advisory Board8.7yrsno datano data
Craig Rademaker
Independent Directorless than a yearno data0.56%
$ 424.0k
Razelle Kurzrock
Member of Scientific Advisory Board8.7yrsno datano data
Andrew Hendifar
Member of Scientific Advisory Board8.7yrsno datano data
Jan-Paul Waldin
Lead Independent Director7.8yrsUS$227.78k0.66%
$ 496.6k
Evangelos Giamarellos-Bourboulis
Member of Scientific Advisory Boardno datano datano data
Mark Rupp
Member of Scientific Advisory Boardno datano datano data
7.5yrs
Average Tenure
69.5yo
Average Age

Experienced Board: XBIT's board of directors are considered experienced (7.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/26 22:20
End of Day Share Price 2025/12/24 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

XBiotech Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kumaraguru RajaNOBLE Capital Markets, Inc.
Joseph CatanzaroPiper Sandler Companies